Please assess the completion status of the following clinical trial:

Trial Title: Trial to Assess Optimized Dosage of Lacosamide as add-on Therapy in Patients With Partial Onset Seizure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has a diagnosis of partial-onset epilepsy with or without secondary generalization~* Currently taking 1 to 3 concomitant marketed antiepileptic drugs~* 18 years and older at study entry~Exclusion Criteria:~* Previous use of lacosamide~* Hypersensitivity to any component of lacosamide~* Patients with partial onset seizures not clearly identifiable~* History of generalized epilepsy~* History of status epilepticus within last 12 months~* Uncountable seizures due to clustering within last 12 weeks~* Non epileptic events, including pseudoseizures, conversion disorder that could be confused with seizures~* History of drug or alcohol abuse~* History of suicide attempt~* Progressive cerebral disease~* Concomitant treatment of felbamate~* Prior or concomitant vigabatrin use~* Under legal protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lacosamide (Type: EXPERIMENTAL): Flexible dosing between 200mg/day and 400mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).